8-K - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

8-K - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

8-K - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

8-A12B/A - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

8-K - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

425 - FS Development Corp. II (0001822711) (Subject)

8-K - FS Development Corp. II (0001822711) (Filer)

425 - FS Development Corp. II (0001822711) (Subject)

425 - FS Development Corp. II (0001822711) (Subject)

8-K - FS Development Corp. II (0001822711) (Filer)

Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19 Gross proceeds made available to Pardes Biosciences from transaction totaled approximately $274 million, combining approximately $199 million of funds held in FS Development Corp. II's trust account and concurrent PIPE financing of $75 million Business combination transaction with FS Development Corp. II, a special purpose acquisition company sponsored by Foresite Capital, completed on December 23, 2021 Combined company renamed Pardes Biosciences, Inc. Common stock commences trading today under ticker symbol "PRDS" on the Nasdaq Global Market CARLSBAD, Calif. and BERKELEY, Calif., Dec. 27, 2021 (G

Proposed merger heads to shareholder vote on December 23rd as ongoing Phase I trial shows potential for unboosted oral regimen In advance of the shareholder vote for the business combination between FS Development Corp. II (NASDAQ:FSII) and Pardes Biosciences, Inc. ("Pardes"), the CEOs of both companies are sharing their thoughts on the COVID-19 public health emergency and how they expect the combined company to play an important role in addressing one of the biggest health crises of our time. "We believe that direct-acting antivirals against coronavirus that are taken orally – such as our PBI-0451 – will become increasingly important in a world where SARS-CoV-2 may become endemic. This e

FS Development Corp. II, a Delaware corporation (the "Company") (NASDAQ:FSII), announced today that its registration statement on Form S-4 (File No. 333-258442) (as amended, the "Registration Statement"), relating to the previously announced business combination (the "Business Combination") with Pardes Biosciences, Inc. ("Pardes"), has been declared effective by the U.S. Securities and Exchange Commission ("SEC") and that it has commenced mailing the definitive proxy statement/prospectus relating to the Special Meeting (the "Special Meeting") of the Company's stockholders to be held on December 23, 2021 in connection with the Business Combination. The proxy statement/prospectus is being mai

CARLSBAD, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical--stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued a new patent No. 11,124,497 (the "'497 patent"), strengthening the Company's intellectual property position for the Company's antiviral drug development program. The ‘497 patent covers compounds designed to inhibit an essential viral protein, the main protease (Mpro) of SARS-CoV-2, the virus causing COVID-19. "We are pleased with the progress in our IP portfolio and our program developments to date. We believe that oral antivirals have the potential to play an important role in ending this pandemic

CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the company's lead candidate, PBI-0451 which is being developed as a potential oral direct-acting antiviral to treat and prevent infections with SARS-CoV-2, the virus that causes COVID-19. PBI-0451 works by inhibiting Viral Main Protease (Mpro), a highly conserved key protein in the virus required for its replication, thus blocking the virus' ability to replicate. The highly conserved nature of Mpro across multiple coronaviruses, including emerging variants of concern such as Delta and Lambda

CARLSBAD, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., an early-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, today announced the appointments of Deborah M. Autor and Laura J. Hamill to its Board of Directors. "I am thrilled to welcome Deb and Laura to our Board. Both bring extensive and unique industry experience to Pardes, as we prepare for the next stage in our company's development," said Uri Lopatin, M.D., Chief Executive Officer of Pardes Biosciences. "Deb possesses a multifaceted background, with broad expertise in regulatory affairs, policy, and quality system

Leading institutional and strategic investors commit $75 million through a common stock private investment in public equity ("PIPE") led by Foresite Capital, as well as Gilead Sciences, RA Capital Management and Frazier Life Sciences Total proceeds from this transaction are expected to be approximately $276 million, combining funds held in FS Development Corp. II's trust account and the PIPE financing, and will be used to advance PBI-0451, Pardes' lead oral antiviral drug candidate to treat and prevent SARS-CoV-2 infections as well as additional candidates from the company's tunable, reversible covalent chemistry platform Business combination is expected to be completed by October 2021

4/A - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

4/A - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

4/A - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

4/A - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

4/A - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

SC 13G - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

SC 13G/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

SC 13D - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

SC 13G - FS Development Corp. II (0001822711) (Subject)

SC 13G - FS Development Corp. II (0001822711) (Subject)